LTRN: Lantern Pharma Long-Term Debt to Capital

The long-term debt-to-equity ratio for Lantern Pharma Inc. (LTRN) on the GURU.Markets platform chart has reached 0.00, confirming the company's authority in targeted oncology therapy. R&D efficiency and target identification via the RADR system are accelerating drug development. The stability of scientific research is ensured by the diversification of laboratories and strict control over the supply of chemical components.

Lantern Pharma Inc. (LTRN) utilizes AI to develop personalized oncology drugs, a process requiring significant investment. This long-term debt-to-equity ratio measures the proportion of loans with maturities exceeding one year relative to equity. An increase in this metric alongside declining capitalization signals a risk of shareholder dilution. Investors should monitor this chart to assess the sustainability of the debt load. Stability in this indicator confirms management's ability to fund development without critical borrowing.